Safety, tolerability and pharmacokinetics of higher‐dose mizoribine in healthy male volunteers

Aims Mizoribine is an oral immunosuppressive agent approved in several countries for prevention of rejection in renal transplantation. Its therapeutic window is based on trough concentrations staying at ≥0.5 but

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of clinical pharmacology 2007-04, Vol.63 (4), p.459-468
Hauptverfasser:	Stypinski, Daria, Obaidi, Mohammad, Combs, Michelle, Weber, Meg, Stewart, Adrian J., Ishikawa, Hiroaki
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adolescent Adult Biological and medical sciences Dose-Response Relationship, Drug Double-Blind Method Humans Immunoglobulins - drug effects immunosuppression Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Immunosuppressive Agents - pharmacokinetics Kidney Transplantation Lymphocytes - drug effects Male Medical sciences Middle Aged mizoribine Pharmacokinetics Pharmacology. Drug treatments renal transplant Ribonucleosides - administration & dosage Ribonucleosides - adverse effects Ribonucleosides - pharmacokinetics safety Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aims Mizoribine is an oral immunosuppressive agent approved in several countries for prevention of rejection in renal transplantation. Its therapeutic window is based on trough concentrations staying at ≥0.5 but
ISSN:	0306-5251 1365-2125
DOI:	10.1111/j.1365-2125.2006.02779.x